Delgocitinib Manufacturing Process: Patent WO2018117152
Patent application WO2018117152 describes a method for preparing delgocitinib, an inhibitor of Janus kinase (JAK) [1]. Delgocitinib is used to treat conditions like atopic dermatitis [2]. The patent outlines a process that aims to improve the efficiency and purity of the delgocitinib synthesis [1].
What does the WO2018117152 patent specifically claim about delgocitinib production?
The patent application details a specific synthetic route for delgocitinib. It focuses on a purification method for a key intermediate, 3-((2-(7-(cyclopropylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-fluorophenoxy)methyl)azetidine, and the final product, delgocitinib [1]. The disclosed process aims to produce delgocitinib with high purity, reducing unwanted byproducts [1].
How does this patent differ from other delgocitinib patents?
While specific details on other delgocitinib patents are not provided, WO2018117152 focuses on a particular manufacturing process. DrugPatentWatch.com tracks various patents related to pharmaceuticals, including those covering active pharmaceutical ingredients (APIs), formulations, and methods of use [3]. Patents like WO2018117152 contribute to the intellectual property landscape by protecting specific aspects of a drug's lifecycle, such as its production [3].
When does delgocitinib's patent protection expire?
Information regarding the specific expiration dates for delgocitinib's patent protection, including that of WO2018117152, is available through specialized patent databases [3]. These databases track the lifecycle of patents, which can be influenced by factors such as patent grants, extensions, and challenges [3].
What are the implications of process patents for drug manufacturing?
Process patents, like WO2018117152, protect the methods used to manufacture a drug. These patents can influence how generic or biosimilar versions of a drug are developed and brought to market. Competitors may need to develop alternative manufacturing processes to avoid infringing on existing process patents [3]. This can impact the cost and timeline for generic entry [3].
Are there any known challenges or litigations related to delgocitinib patents?
Information regarding specific challenges or litigations for delgocitinib patents, including WO2018117152, can be found through legal and patent tracking services [3]. Patent litigation is a common aspect of the pharmaceutical industry, where companies may challenge existing patents to clear the way for their products or defend their own intellectual property [3].
How is delgocitinib used in medicine?
Delgocitinib is a topical JAK inhibitor approved for treating atopic dermatitis [2]. It works by modulating the immune response that contributes to the inflammation and itching associated with this skin condition [2].
Sources:
1. WO2018117152
2. https://www.drugpatentwatch.com/drug/delgocitinib
3. https://www.drugpatentwatch.com/